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Abstract
Objective: Osteoprotegerin (OPG) acts as an important regulatory molecule in atherosclerosis. Recent
studies report that thiazolidinediones could affect OPG expression. We investigated the relationship
between OPG and inﬂammatory cytokines and the effects of pioglitazone (a PPARg (PPARG) agonist)
versus metformin on serum OPG levels in type 2 diabetic patients.
Design and methods: Sixty-seven type 2 diabetic patients were included in this study. They were assigned
to pioglitazone (15 mg/day, nZ34) or metformin (1000 mg/day, nZ33) during 24 weeks. Various
anthropometric and metabolic parameters, OPG, interleukin 6 (IL6), C-reactive protein (CRP),
adiponectin, and homeostasis model assessment of insulin resistance (HOMA-IR), were measured at
baseline and at 6 months of treatment.
Results: Serum OPG levels correlated signiﬁcantly with fasting plasma glucose (FPG), HbAlc, HOMA-
IR, IL6, and CRP, and inversely correlated with adiponectin after adjusting for age (P!0.05). Multiple
regression analysis showed that FPG, HbAlc, and adioponectin were independently correlated with
OPG level. After 6 months of treatment, the reduction in FPG and HbAlc levels was similar between the
two groups. Pioglitazone treatment signiﬁcantly increased body mass index (P!0.05) and waist
circumference (P!0.05) and decreased triglycerides (P!0.05) and HOMA-IR (P!0.01). The
adiponectin concentration was increased (P!0.05), and OPG and CRP levels were decreased in the
pioglitazone group (P!0.05), but were unchanged in the metformin group. The changes in serum
OPG in the pioglitazone group showed signiﬁcant correlation with changes in FPG, HbAlc, and
adiponectin.
Conclusions: In type 2 diabetic patients, pioglitazone decreases OPG levels, and this decrease in OPG
levels might be associated with the increase in adiponectin.
European Journal of Endocrinology 164 69–74
Introduction
Patients with type 2 diabetes mellitus are at high risk
for coronary heart disease, cerebrovascular disease,
and peripheral vascular disease, with a two- to six-fold
higher risk of developing these disorders than
individuals without diabetes (1). These atherosclerotic
diseases are common causes of morbidity and
mortality among people with diabetes. Atherosclerosis
is known to be an inﬂammatory disease, and many
clinical studies have demonstrated a relationship
between inﬂammatory markers and the risk of
cardiovascular disease (2).
Osteoprotegerin (OPG) is a glycoprotein belonging to
the tumor necrosis factor receptor superfamily, which
was originally discovered as an inhibitor of bone
resorption. OPG acts as a decoy receptor of the receptor
activator of the nuclear factor kB ligand, thereby
inhibiting osteoclastogenesis (3–5). OPG is mainly
secreted by bone, but is also secreted by a variety of
different tissues including endothelial cells and smooth
muscle cells (6, 7). Recent studies have shown that OPG
also acts as an important regulatory molecule in
vascular disease, and increased serum OPG levels are
associated with cardiovascular disease in the general
population, as well as in diabetic patients (8, 9).
Epidemiological studies demonstrate a relationship
between OPG level and the severity of coronary
atherosclerosis (10, 11). Based on these data, it is likely
that OPG plays an important role in atherosclerosis and
could be a marker of atherosclerosis.
Thiazolidinediones (TZDs), including pioglitazone,
improve insulin sensitivity and glycemic control in
type 2 diabetic patients. In addition, patients treated
with TZDs show improved endothelial function,
decreased inﬂammation, and decreased plasma levels
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atherogenic effects (12–14). Activation of peroxisome
proliferator-activated receptor-g (PPAR-g or PPARG)
prevents both OPG expression in human aortic smooth
muscle cells (15) and differentiation of mesangial
precursors into osteoblastic cells (16). Together, these
data suggest that TZDs might reduce OPG plasma levels,
as suggested in a more recent study (17). The purposes
of this study are to analyze the relationship between
OPG and inﬂammatory cytokines and to investigate the
effects of pioglitazone versus metformin on serum OPG
levels in type 2 diabetic patients.
Subjects and methods
Subjects
Sixty-seven Korean patients with type 2 diabetes
mellitus were recruited from the Diabetes Clinic of
Kangnam Severance Hospital. The diagnosis of type
2 diabetes was based on a previous history of
diabetes or the criteria by the American Diabetes
Association’sdiagnosticguidelines.Patientsaged40–70
years with type 2 diabetes inadequately managed
with glimepiride R2 mg or equivalent dose of other
sulfonylurea (e.g. gliclazide MR 30 mg) and with
stable or worsening glycemic control for R3 months
were eligible if their HbAlc was between 7.0 and 10.0%
and their fasting C-peptide was R1.5 ng/ml at
screening. Exclusions included patients with type 1
diabetes or ketoacidosis, symptomatic heart failure,
malignant disease in the previous 10 years, and
renal failure.
Subjectswereopenlabelrandomizedintopioglitazone
(15 mg/day, nZ34) and metformin (1000 mg/day,
nZ33) treatment groups. The Institutional Review
Board of Yonsei University College of Medicine approved
the study protocol, and all of the subjects participated
in this study that was carried out following the
recommendations of the declaration provided informed
consent prior to the start of this study. Patients were
enrolled after an initial screening visit. All study
measurements were obtained upon entry into the
study and at the end of a 24-week observation period.
Clinical characteristics
Body weight and height were measured in the morning
with participants wearing light clothing. Body mass
index (BMI) was calculated as weight (kg)/height (m)
2.
Waist circumference (WC) was measured at the mid
point between the lower border of the rib cage and the
iliac crest. The patients’ past medical histories were
evaluated; the duration of diabetes, concomitant
diseases, and the drugs currently being taken were
assessed. Systolic and diastolic blood pressures (SBPand
DBP) were measured after a 5 min rest.
Biochemical parameters
All measurements were obtained in the morning, after
the patient had fasted since midnight. Blood samples
were immediately centrifuged, and serum samples
were stored at K70 8C until laboratory testing. HbAlc
was determined by HPLC (Variant II, Bio-Rad).
Glucose was measured with a standard glucose
oxidase reference method (747 automatic analyzer,
Hitachi). Fasting serum insulin was determined by
chemiluminescence (RIA kit, Daiichi, Tokyo, Japan).
Total cholesterol, high-density lipoprotein (HDL)
cholesterol, and triglycerides (TG) were measured
with an enzymatic color test (Daiichi, Hitachi 747),
and low-density lipoprotein (LDL) cholesterol was
calculated according to the Friedewald formula.
Insulin resistance was calculated by homeostasis
model assessment of insulin resistance (HOMA-IR)
analysis, HOMA-IRZfasting insulin (mU/ml)!fasting
plasma glucose (mmol/l)/22.5. Serum OPG levels were
measured using a human OPG ELISA kit (Biomedica,
Vienna, Austria). C-reactive protein (CRP) levels were
measured using a Quantikine CRP kit (R&D Systems,
Minneapolis, MN, USA), and interleukin 6 (IL6) levels
were determined using a Quantikine HS IL6 kit (R&D
Systems). Plasma adiponectin levels were measured by
ELISA (Mesdia, Seoul, Korea).
Table 1 Baseline characteristics of the study subjects. Data are
meanGS.D.
PIO-treated
group (nZ34)
MET-treated
group (nZ33)
Sex (M/F) 18/16 17/16
Ages (years) 62.3G8.0 63.1G8.4
DM duration (years) 5.1G5.0 4.9G5.3
BMI (kg/m
2) 25.5G3.8 25.2G3.0
WC (cm) 92.6G6.2 93.1G5.4
SBP (mmHg) 128.3G19.7 126.9G18.8
DBP (mmHg) 74.5G13.4 75.3G15.6
FPG (mmol/l) 7.7G1.7 7.5G1.5
Insulin (mU/l) 10.2G2.7 9.9G2.5
HbAlc (%) 8.3G0.3 8.2G0.4
Creatinine (mmol/l) 86.0G12.4 85.3G14.7
TC (mmol/l) 4.8G0.7 4.7G0.7
TG (mmol/l) 1.9G0.7 1.8G0.8
HDL-C (mmol/l) 1.1G0.2 1.2G0.2
LDL-C (mmol/l) 2.9G0.6 2.8G0.6
AST (IU/l) 23.8G6.1 23.1G8.2
ALT (IU/l) 25.8G11.1 25.3G10.6
HOMA-IR 3.49G1.62 3.46G1.48
Adiponectin (mg/ml) 5.48G3.24 5.71G4.21
OPG (pmol/l) 3.73G1.12 3.65G1.20
IL6 (pg/ml) 1.78G1.32 1.73G1.10
CRP (mg/ml) 1.73G1.30 1.74G1.07
PIO, pioglitazone; MET, metformin; BMI, body mass index; WC, waist
circumference; FPG, fasting plasma glucose; TC, total cholesterol; TG,
triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood
pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase;
HOMA-IR, homeostasis model assessment of insulin resistance; OPG,
osteoprotegerin; IL6, interleukin 6; CRP, C-reactive protein.
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Data are expressed as the meanGS.D. Statistical analysis
was performed with unpaired or paired Student’s t-tests.
Pearson’s correlation coefﬁcients were used to estimate
the correlations between serum OPG concentration,
physical measurements, clinical characteristics, and
insulin resistance. The linear correlations were ana-
lyzed after logarithmic transformation for the variables
not normally distributed. Stepwise multiple linear
regression analysis was performed to analyze the
inﬂuence of different factors on OPG. Statistical analyses
were conducted using SPSS for Windows, version 11.0
(SPSS, Inc., Chicago, IL, USA), and P!0.05 was
considered statistically signiﬁcant.
Results
The two treatment groups were similar with respect to
age, gender distribution, duration of diabetes mellitus,
HbAlc, BMI, lipid proﬁle, SBP, DBP, baseline insulin
sensitivity, adiponectin, OPG, IL6, and CRP (Table 1).
According to baseline data, serum OPG levels in diabetic
patients correlated signiﬁcantly with age, fasting
plasma glucose (FPG), HbAlc, HOMA-IR, adiponectin,
IL6, and CRP. These correlations persisted after
adjustment for age (Table 2). Multiple regression
analysis showed that FPG (bZ0.16, P!0.01), HbAlc
(bZ0.11, PZ0.04), and adioponectin (bZK0.13,
PZ0.03) were independently correlated with OPG
levels. The adjusted r
2 was 21.3%.
After 6 months of treatment, there were no
differences in the improvements of FPG and HbAlc
from baseline by both drugs. Treatment with pioglita-
zone signiﬁcantly increased BMI and WC and decreased
insulin, TG levels, and HOMA-IR. Plasma adiponectin
concentrations were increased in the pioglitazone group
but were unchanged in the metformin group. Plasma
levels of OPG and CRP decreased in the pioglitazone
group but were unchanged in the metformin group
(Table 3 and Fig. 1).
Table 2 Correlations between OPG and other variables (r
1) and
after correction for age (r
2).
r
1 r
2
Age 0.25* NA
BMI 0.17 0.14
WC 0.09 0.07
SBP 0.11 0.09
DBP 0.11 0.10
FPG 0.28
† 0.26
†
Insulin 0.15
a 0.12
a
HbAlc 0.23
† 0.20*
HOMA-IR 0.21*
,a 0.16*
,a
Creatinine 0.09 0.02
TC 0.18 0.16
TG 0.08
a 0.07
a
HDL-C K0.17 K0.12
LDL-C 0.06 0.05
AST 0.06 0.03
ALT 0.05 0.04
Adiponectin K0.27
†,a K0.22
†,a
IL6 0.15*
,a 0.12*
,a
CRP 0.18*
,a 0.11*
,a
*P!0.05,
†P!0.01.
aPearson correlation was used after logarithmic transformation for these
variables.
Table 3 Effect of each agent on clinical and biochemical characteristics. Data are meanGS.D.
PIO-treated group (nZ34) MET-treated group (nZ33)
Before After Before After
BMI (kg/m
2) 25.5G3.8 26.3G3.2* 25.2G3.0 24.8G2.9
WC (cm) 92.6G6.2 96.9G7.3* 93.1G5.4 92.2G6.6
SBP (mmHg) 128.3G19.7 130.2G19.5 126.9G18.8 129.4G23.1
DBP (mmHg) 74.5G13.4 76.5G16.7 75.3G15.6 78.4G15.9
FPG (mmol/l) 7.7G1.7 6.3G1.7
† 7.5G1.5 6.5G1.2
†
Insulin (mU/l) 10.2G2.7 5.8G2.5
† 9.9G2.5 9.0G1.8
HbAlc (%) 8.3G0.3 7.5G0.6* 8.2G0.4 7.4G0.4*
Creatinine (mmol/l) 86.0G12.4 85.6G11.8 85.3G14.7 86.1G10.7
TC (mmol/l) 4.8G0.7 4.5G0.6 4.7G0.7 4.6G0.5
TG (mmol/l) 1.9G0.7 1.4G0.8* 1.8G0.8 1.7G0.7
HDL-C (mmol/l) 1.1G0.2 1.3G0.4 1.2G0.2 1.1G0.2
LDL-C (mmol/l) 2.9G0.6 2.5G0.5 2.8G0.6 2.4G0.5
AST (IU/l) 23.8G6.1 24.3G5.8 23.1G8.2 23.5G6.4
ALT (IU/l) 25.8G11.1 25.5G8.9 25.3G10.6 24.7G9.5
HOMA-IR 3.49G1.62 1.63G1.01
† 3.46G1.48 2.86G1.55
Adiponectin (mg/ml) 5.48G3.24 9.78G6.26
† 5.71G4.21 6.95G4.27
OPG (pmol/l) 3.73G1.12 2.54G0.78* 3.65G1.20 3.34G0.83
IL6 (pg/ml) 1.78G1.32 1.50G0.97 1.73G1.10 1.39G0.39
CRP (mg/ml) 1.73G1.30 1.23G0.75* 1.74G1.07 1.52G0.69
*P!0.05 for comparison of data before and after treatment.
†P!0.01 for comparison of data before and after treatment.
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calculated as the difference in values; the absolute
changes in serum OPG in the pioglitazone group
showed signiﬁcant correlation with changes in FPG,
HbAlc, and adiponectin (Table 4).
Discussion
In this study, we showed that serum OPG level inversely
correlates with adiponectin, and pioglitazone treatment
increases adiponectin and decreases OPG and CRP
levels. Moreover, changes in serum OPG in the
pioglitazone group showed signiﬁcant correlations
with changes in FPG, HbAlc, and adiponectin.
Several recent studies have identiﬁed a relationship
between OPG and human vascular biology. Browner
et al. (18) reported that a high serum OPG level is
associated with increased cardiovascular mortality, and
Xiang et al. (19) demonstrated its relationship with
endothelial dysfunction, which is an important early
event in atherosclerosis (20). In addition, patients with
type 2 diabetes, who are at a two- to six-fold increased
risk for cardiovascular disease (1), were shown to have
a higher serum OPG level compared with subjects
without diabetes (19, 21). Moreover, Avignon et al. (22)
found that OPG is an independent predictor of coronary
artery disease in patients with type 2 patients.
Hyperglycemia and elevated HbAlc are well
known cardiovascular risk factors, and we found
that plasma OPG levels positively correlated with
FPG and HbAlc, in agreement with previous studies
(19, 21). As expected, based on results of previous
studies (21, 23), our results also conﬁrmed a positive
relationship between OPG and HOMA-IR.
Inﬂammation plays a major role in diabetes-induced
atherosclerosis (24). CRP is an inﬂammatory marker,
which is produced predominantly by hepatocytes under
the inﬂuence of cytokines, and the inﬂammatory
cytokine IL6, which is secreted by adipose tissue,
stimulates CRP production in the liver. In this study,
we showed a positive relationship between OPG and
both CRP and IL6 in type 2 diabetes, consistent with
previous reports that serum OPG levels are correlated
with CRP (21, 23) and IL6 (21). Adiponectin is an
important adipocytokine with anti-inﬂammatory and
anti-atherogenic properties, which modulates insulin
resistance (25). Clinical studies have shown that
adiponectin levels are lower in individuals with
cardiovascular disease (26), but the relationship
between adiponectin and OPG remains unclear.
Gannage ´-Yared et al. (23) reported no signiﬁcant
association between adiponectin and OPG in obese
and non-obese populations. Another study showed a
positive association between adiponectin and OPG in
an aging male population but did not show a
correlation between OPG and coronary artery disease
(27). In contrast, Hofsø et al. (28) reported that OPG
levels are negatively correlated with adiponectin levels.
In this study, we report an inverse correlation between
adiponectin and OPG levels in type 2 diabetes. Sodi et al.
(29) showed that adiponectin may negatively affect
osteoblast production of OPG and in vitro studies have
shown that adiponectin inhibits OPG production in
human osteoblasts (30). Jurimae et al. (31) suggested
that adiponectin could be involved in bone weakening.
TZDs act as agonists of PPAR-g and are powerful
insulin sensitizers, which have been used as antidiabetic
agents. PPAR-g agonists, such as pioglitazone, cause a
marked increase in adiponectin gene expression in
adipocytes and also have anti-inﬂammatory and anti-
atherogenic properties (32). In this study, patients with
type 2 diabetes, who were treated with pioglitazone and
metformin, had comparable FPG and HbAlc values
before and after the study, thus, glycemic control, as
determined by FPG and HbAlc, did not differ between
the groups. Treatment with pioglitazone for 24 weeks
increased adiponectin levels and decreased levels of
CRP and OPG in patients with type 2 diabetes, and this
effect was presumably independent of glycemic control.
Several limitations of this study need to be considered,
the major one being the small number of patients
involved and the low dose of pioglitazone used. In
addition, we showed data foronly 24 weeks of treatment
with pioglitazone, which may not necessarily reﬂect the
results of long-term treatment. Third, due to the lack of
normal glucose tolerance control group, we could not
analyze the relationship between OPG and metabolic
parameters and inﬂammatory cytokines in the control
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Figure 1 Effects of pioglitazone and metformin at 24 weeks on
serum OPG (*P!0.05). P values are Student’s t-test, showing a
signiﬁcant decrease for the pioglitazone group.
Table 4 Correlations between changes in OPG and changes in
other variables in the pioglitazone-treated group.
rP
FPG 0.27 !0.01
HbAlc 0.12 0.04
Adiponectin K0.21 0.03
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group and type 2 diabetic patients. Finally, because
endothelial or osteoblast OPG expression was not
measured, the precise relationship between serum
OPG levels and vascular integrity and bone metabolism
could not evaluated.
In conclusion, pioglitazone decreases OPG level, and
this decrease in OPG level is associated with the increase
in adiponectin. Further studies are needed to elucidate
the observed relationships.
Declaration of interest
The authors declare that there is no conﬂict of interest that could be
perceived as prejudicing the impartiality of the research reported.
Funding
This study was supported by a faculty research grant of Yonsei
University College of Medicine for 2007 and Yonsei University College
of Medicine, Internal Medicine Research Grant 2007.
References
1 Kannel WB & McGee DL. Diabetes and cardiovascular disease; the
Framingham study. Journal of the American Medical Association
1979 241 2035–2038. (doi:10.1001/jama.241.19.2035)
2 Willerson JT & Ridker PM. Inﬂammation as a cardiovascular
risk factor. Circulation 2004 109 2–10. (doi:10.1161/01.CIR.
0000122867.89751.59)
3 Hofbauer LC & Heufelder AE. The role of receptor activator of
nuclear factor-kB ligand and osteoprotegerin in the pathogenesis
and treatment of metabolic bone diseases. Journal of Clinical
Endocrinology and Metabolism 2000 85 2355–2363. (doi:10.
1210/jc.85.7.2355)
4 Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T &
Higashio K. Isolation of a novel cytokine from human ﬁbro-
blasts that speciﬁcally inhibits osteoclastogenesis. Biochemical and
Biophysical Research Communications 1997 234 137–142. (doi:10.
1006/bbrc.1997.6603)
5 Kwon BS, Wang S, Udagawa N, Haridas V, Lee ZH, Kim KK, Oh KO,
Greene J, Li Y, Su J, Gentz R, Aggarwal BB & Ni J. TR1, a new
member of the tumor necrosis factor receptor superfamily, induces
ﬁbroblast proliferation and inhibits osteoclastogenesis and bone
resorption. FASEB Journal 1998 12 845–854.
6 Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC,
O’Brien T & Khosla S. Effects of immunosuppressants on receptor
activatorof NF-Bligandandosteoprotegerinproductionby human
osteoblastic and coronary artery smooth muscle cells. Biochemical
and Biophysical Research Communications 2001 280 334–339.
(doi:10.1006/bbrc.2000.4130)
7 Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W &
Osdoby P. Receptor activator of NF-B and osteoprotegerin
expression by human microvascular endothelial cells, regulation
by inﬂammatory cytokines, and role in human osteoclastogenesis.
Journal of Biological Chemistry 2001 276 20659–20672. (doi:10.
1074/jbc.M010153200)
8 Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M,
Mayr A, Santer P, Smolen J, Poewe W & Willeit J. Osteoprotegerin is
a risk factor for progressive atherosclerosis and cardiovascular
disease. Circulation 2004 109 2175–2180. (doi:10.1161/01.CIR.
0000127957.43874.BB)
9 Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE &
Rasmussen LM. Increased plasma concentrations of
osteoprotegerin in type 2 diabetic patients with microvascular
complications.EuropeanJournal ofEndocrinology2003 14939–42.
(doi:10.1530/eje.0.1490039)
10 Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K & Nishizawa Y.
Serum osteoprotegerin levels are associated with the presence
and severity of coronary artery disease. Circulation 2002 106
1192–1194. (doi:10.1161/01.CIR.0000031524.49139.29)
11 Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B &
Hofbauer LC. Increased osteoprotegerin serum levels in men
with coronary artery disease. Journal of Clinical Endocrinology
and Metabolism 2003 88 1024–1028. (doi:10.1210/jc.2002-
020775)
12 Yki-Jarvinen H. Thiazolidinediones. New England Journal of
Medicine 2004 351 1106–1118. (doi:10.1056/NEJMra041001)
13 Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C
& Staels B. Pleiotropic actions of peroxisome proliferator-activated
receptors in lipid metabolism and atherosclerosis. Arteriosclerosis,
Thrombosis, and Vascular Biology 2002 22 717–726. (doi:10.
1161/01.ATV.0000015598.86369.04)
14 Martens FM, Visseren FL, Lemay J, De Koning EJ & Rabelink TJ.
Metabolic and additional vascular effects of thiazolidinediones.
Drugs 2002 62 1463–1480. (doi:10.2165/00003495-200262
100-00004)
15 Fu M, Zhang J, Lin YG, Zhu X, Willson TM & Chen YE. Activation
of peroxisome proliferator-activated receptor [gamma] inhibits
osteoprotegerin gene expression in human aortic smooth muscle
cells. Biochemical and Biophysical Research Communications 2002
294 597–601. (doi:10.1016/S0006-291X(02)00533-8)
16 Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA,
Manolagas SC & Jilka RL. Inhibition of Osf2/Cbfa1 expression and
terminal osteoblast differentiation by PPAR gamma. Journal of
Biological Chemistry 1999 74 357–371. (doi:10.1002/(SICI)
1097-4644(19990901)74:3!357::AID-JCB5O3.0.CO;2-7)
17 Sultan A, Avignon A, Galtier F, Piot C, Mariano-Goulart D,
Dupuy AM & Cristol JP. Osteoprotegerin, thiazolidinediones
treatment, and silent myocardial ischemia in type 2 diabetic
patients. Diabetes Care 2008 31 593–595. (doi:10.2337/dc07-
1771)
18 Browner WS, Lui LY & Cummings SR. Associations of
serum osteoprotegerin levels with diabetes, stroke, bone density,
fracture, and mortality in elderly women. Journal of Clinical
Endocrinology and Metabolism 2001 86 631–637. (doi:10.1210/
jc.86.2.631)
19 Xiang GD, Xu L, Zhao LS, Yue L & Hou J. The relationship between
plasma osteoprotegerin and endothelium dependent arterial
dilation in type 2 diabetes. Diabetes 2006 55 2126–2131.
(doi:10.2337/db06-0231)
20 Boneti PO, Lerman LO & Lerman A. Endothelial dysfunction,
a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis,
and Vascular Biology 2003 23 168–175. (doi:10.1161/01.ATV.
0000051384.43104.FC)
21 Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH,
Baik SH, Choi DS & Choi KM. Serum osteoprotegerin levels are
associated with inﬂammation and pulse wave velocity. Clinical
Endocrinology 2005 63 594–598. (doi:10.1111/j.1365-2265.
2005.02390.x)
22 Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP & Dupuy AM.
Osteoprotegerin is associated with silent coronaryarterydiseasein
high-risk but asymptomatic type 2 diabetic patients. Diabetes Care
2005 28 2176–2180. (doi:10.2337/diacare.28.9.2176)
23 Gannage ´-YaredMH,YaghiC,HabreB,KhalifeS,NounR,Germanos-
Haddad M & Trak-Smayra V. Osteoprotegerin in relation to body
weight, lipid parameters insulin sensitivity, adipocytokines, and
C-reactive protein in obese and non-obese young individuals: results
from both cross-sectional and interventional study. European Journal
of Endocrinology 2008 158 353–359. (doi:10.1530/EJE-07-0797)
24 Libby P & Ridker PM. Inﬂammation and atherosclerosis: role of
C-reactive protein in risk assessment. American Journal of Medicine
2004 116 9S–16S. (doi:10.1016/j.amjmed.2004.02.006)
PPAR-g agonist and OPG levels in type 2 diabetes 73 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164
www.eje-online.org25 Gil-Campos M, Canete R & Gil A. Adiponectin, the missing
link in insulin resistance and obesity. Clinical Nutrition 2004 23
963–974. (doi:10.1016/j.clnu.2004.04.010)
26 Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y,
Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S,
Funahashi T & Matsuzawa Y. Novel modulator for endothelial
adhesion molecules: adipocyte-derived plasma protein adiponec-
tin. Circulation 1999 100 2473–2476.
27 Gannage ´-Yared MH, Fares F, Semaan M, Khalife S & Jambart S.
Circulating osteoprotegerin is correlated with lipid proﬁle, insulin
sensitivity, adiponectin and sex steroids in an ageing male
population. Clinical Endocrinology 2006 64 652–658. (doi:10.
1111/j.1365-2265.2006.02522.x)
28 Hofsø D, Ueland T, Hager H, Jenssen T, Bollerslev J, Godang K,
Aukrust P, Røislien J & Hjelmesaeth J. Inﬂammatory mediators in
morbidly obese subjects: associations with glucose abnormalities
and changes after oral glucose. European Journal of Endocrinology
2009 161 451–458. (doi:10.1530/EJE-09-0421)
29 SodiR,HazellMJ,DurhamBH,ReesC,RanganathLR&FraserWD.
The circulating concentration and ratio of total and high
molecular weight adiponectin in post-menopausal women with
and without osteoporosis and its association with body mass index
andbiochemical markers ofbonemetabolism.ClinicalBiochemistry
2009 42 1375–1380. (doi:10.1016/j.clinbiochem.2009.06.003)
30 Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD & Liao EY.
Adiponectin stimulates RANKL and inhibits OPG expression in
human osteoblasts through the MAPK signalling pathway.
Journal of Bone and Mineral Research 2006 21 1648–1658.
(doi:10.1359/jbmr.060707)
31 Jurimae J, Rembel K, Jurimae T & Rehand M. Adiponectin is
associated with bone mineral density in perimenopausal women.
Hormoneand MetabolicResearch 200537 297–302.(doi:10.1055/
s-2005-861483)
32 Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D,
Konrad T & Forst T. Improvement of cardiovascular risk markers
by pioglitazone is independent from glycemic control: results from
the pioneer study. Journal of the AmericanCollege of Cardiology 2005
45 1925–1931. (doi:10.1016/j.jacc.2005.03.041)
Received 6 October 2010
Accepted 20 October 2010
74 J S Park and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164
www.eje-online.org